ОЦІНЮВАННЯ ВІДПОВІДІ ПАЦІЄНТІВ З НИРКОВО-КЛІТИННИМ РАКОМ НА ІНГІБІТОРИ ТИРОЗИНКІНАЗ ЗА ЕКСПРЕСІЄЮ мікроРНК-99b, -144, -210, -222, -302а та -377 В ПУХЛИННІЙ ТКАНИНІ

• Datum: 2023
• Hauptverfasser: Vitruk, Yu.V., Semko, S.L., Voylenko, O.A., Pikul, M.V., Borikun, T.V., Zadvornyi, T.V., Yalovenko, T.M., Stakhovsky, E.O., Rossylna, O.V.
• Format: Artikel
• Sprache: English
• Veröffentlicht: PH Akademperiodyka 2023
• Schlagworte: мікроРНК; нирково-клітинний рак; таргетна терапія.
• Online Zugang: https://exp-oncology.com.ua/index.php/Exp/article/view/2021-2-4
• Назва журналу: Experimental Oncology

Background: Renal cell carcinoma (RCC) is one of the most common solid tumors in adults highly resistant to conventional therapies. The expression profile of a number of miRNAs correlates with RCC response to chemotherapeutic agents. Aim: To identify the association of tumor miRNAs expression with neoadjuvant treatment response in patients with RCC. Materials and Methods: We analyzed the expression levels of tumor miR-99b, -144, -155, -210, -222, -302а, -377 in 93 RCC patients who received pazopanib or sunitinib in neoadjuvant regimen using RT-PCR. RNU48 was used as a reference miRNA. Results: The levels of expression of miR-99b and -377 are associated with the RCC response to pazopanib, and microRNA-210 and -377 to sunitinib. The characteristic expression profile of miR-99b, -144, -222, -377, and miR-302a determined in 90% of cases was delineated in pazopanib responders as opposed to nonresponders. Similarly, the characteristic expression profile of miR-210, -222, -302a and -377 was suggested for sunitinib responders. Conclusions: Levels of miR-99b, -210 and -377 expression in RCC tumor tissue might be used as a basis for future predictive panel intended for the assessment of the sensitivity to the regimens of neoadjuvant RCC treatment.